Celldex Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CLDX$31.24+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| Exhibit No. | | Description |
| *31.1 | | Certification of President and Chief Executive Officer. |
| *31.2 | | Certification of Senior Vice President and Chief Financial Officer. |
| **32.1 | | Section 1350 Certifications. |
| *101.INS | | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| *101.SCH | | Inline XBRL Taxonomy Extension Schema Document. |
| *101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| *101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| *101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| *101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101). |
| * | Filed herewith. |
|---|
**Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.